Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Oncology

• Publication date

  2007-07-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.11.3449PMID 17617523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

  2007cited by this paper
• Does a BRCA mutation plus tamoxifen equal hysterectomy?

  2007cited by this paper
• Management of Miscarriage: Expectant, Medical, or Surgical? Results of Randomised Controlled Trial (Miscarriage Treatment [MIST] Trial)

  2006cited by this paper
• Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.

  2006cited by this paper
• Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

  2006cited by this paper
• Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer.

  2006cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

  2006cited by this paper
• Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.

  2006cited by this paper
• Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

  2005cited by this paper
• Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2005cited by this paper
• Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

  2005cited by this paper
• Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.

  2005cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

  2005cited by this paper
• Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

  2005cited by this paper
• Bilateral oophorectomy and breast cancer risk reduction among women with a family history.

  2004cited by this paper
• Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

  2004cited by this paper
• HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.

  2004cited by this paper
• Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

  2004cited by this paper
• BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.

  2004cited by this paper
• Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?

  2004cited by this paper
• Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

  2004cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.

  2003cited by this paper
• Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

  2002cited by this paper
• Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

  2002cited by this paper
• Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

  2002cited by this paper
• Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

  2002cited by this paper
• Cancer incidence in a population of Jewish women at risk of ovarian cancer.

  2002cited by this paper
• Oophorectomy for breast cancer: history revisited.

  2002cited by this paper
• Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status

  2001cited by this paper
• Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Risk of endometrial carcinoma associated with BRCA mutation.

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

  2000cited by this paper
• Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?

  2000cited by this paper
• Ovarian remnant syndrome after laparoscopic oophorectomy

  2000cited by this paper
• Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

  2000cited by this paper
• Ovarian cancer developing in the ovarian remnant syndrome. A case report and literature review

  2000cited by this paper
• Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

  2000cited by this paper
• Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors.

  1999cited by this paper
• Ovarian remnant syndrome after laparoscopic oophorectomy.

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.

  1998cited by this paper
• Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

  1998cited by this paper
• Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

  1998cited by this paper
• Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer.

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

  1997cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2

  1997cited by this paper
• Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993.

  1996cited by this paper
• Prophylactic oophorectomy in inherited breast/ovarian cancer families.

  1995cited by this paper
• Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

  1993cited by this paper
• Ovarian remnant syndrome. A case report of a malignancy

  1992cited by this paper
• [Ovarian cancer in ovarian remnant syndrome?].

  1992cited by this paper
• [Ovarian remnant syndrome. A case report of a malignancy].

  1992cited by this paper
• Ovarialkarzinom bei Ovarian Remnant syndrome

  1992cited by this paper
• Ovarialkarzinom bei Ovarian Remnant Syndrome

  1991cited by this paper
• [Ovarian cancer in ovarian remnant syndrome].

  1991cited by this paper
• [Adenocarcinoma of the ovary in the ovarian remnant syndrome].

  1990cited by this paper
• Menstrual factors and risk of breast cancer.

  1988cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper
• Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families.

  1982cited by this paper
• Breast cancer and artificial menopause: a cohort study.

  1968cited by this paper
• Ovarian cancer in mother and five daughters.

  1950cited by this paper

• Current insights into breast and ovarian cancer risk: a contemporary review.

  2025cites this paper
• Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinoma

  2025cites this paper
• Associated risk and resilience factors of Alzheimer’s disease in women with early bilateral oophorectomy: Data from the UK Biobank

  2024cites this paper
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis

  2023cites this paper
• Comprehensive Care of Women With Genetic Predisposition to Breast and Ovarian Cancer.

  2023cites this paper
• Serous tubal intra‐epithelial carcinoma: what do we really know at this point?

  2022cites this paper
• Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of In Vivo Fallopian Tube Electroporation and CRISPR-Cas9–Mediated Genome Editing

  2021cites this paper
• Does genetic testing have any role for elderly breast cancer patients? A narrative review

  2021cites this paper
• Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing

  2021cites this paper
• Krukenberg Tumors From Breast Cancer – Literature Review

  2020cites this paper
• Carcinoma of the Ovaries and Fallopian Tubes

  2020cites this paper
• Genetic testing for epithelial ovarian cancer.

  2020cites this paper
• Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers

  2019cites this paper
• Awareness and acceptability of population-based screening for pathogenic BRCA variants: Do race and ethnicity matter?

  2019cites this paper
• Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.

  2019cites this paper
• Epithelial Ovarian Cancer Prevention

  2019cites this paper
• BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14

  2019cites this paper
• A Comprehensive Review of Ovarian Serous Carcinoma

  2019cites this paper
• Familial Pancreatic Cancer and Surveillance of High-Risk Individuals

  2019cites this paper
• Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.

  2019cites this paper
• Diseases of the Fallopian Tube and Paratubal Region

  2019cites this paper
• Peritoneal cancer after bilateral mastectomy, hysterectomy, and bilateral salpingo-oophorectomy with a poor prognosis: A case report and review of the literature

  2019cites this paper
• Non-Neoplastic Lesions that may Mimic Serous Tubal Intra-Epithelial and Invasive Carcinoma of the Fallopian Tube: Morphological and Immunohistochemical Analysis

  2018cites this paper
• Title Familial pancreatic cancer: Concept, management and issues

  2018cites this paper
• Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.

  2018cites this paper
• Ovarian Cancer Prevention in High-risk Women

  2017cites this paper
• Familial pancreatic cancer: Concept, management and issues

  2017cites this paper
• ISGylation and EGFR Signaling is Modulated by BRCA1 Expression and Follicular Fluid Exposure in Human Fallopian Tube Epithelium

  2017cites this paper
• Longitudinal Change in Cognitive Performance of Women Post-Oophorectomy

  2017cites this paper
• “Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty”

  2017cites this paper
• Use of hormone replacement therapy after risk‐reducing salpingo‐oophorectomy

  2017cites this paper
• Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.

  2016cites this paper
• Facteurs génétiques à prendre en considération dans le cadre de l'examen gynécologique annuel.

  2016cites this paper
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

  2016cites this paper
• Population‐based analysis of colorectal cancer risk after oophorectomy

  2016cites this paper
• Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers

  2016cites this paper
• Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer

  2016cites this paper
• Endocrine interventions in women with BRCA1/2 mutations

  2016cites this paper
• Evaluation of the Effect of Alfalfa Extract on Breast Cancer

  2015cites this paper
• Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer

  2015influential citation
• Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models

  2015cites this paper
• Clinical characteristics and prognostic analysis of Krukenberg tumor.

  2015cites this paper
• WT1 role in mammary gland and breast cancer biology

  2015cites this paper
• A Comprehensive Approach to the Identification and Management of the BRCA Patient

  2015cites this paper
• Biomarkers for Early Detection of Familial Breast Cancer

  2015cites this paper
• Targeting the Mevalonate Pathway to Reduce Mortality from Ovarian Cancer

  2015cites this paper
• Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

  2015cites this paper
• Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies

  2015cites this paper
• Hormone therapy in oophorectomized BRCA1/2 mutation carriers

  2014cites this paper
• Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer

  2014cites this paper
• Gynecologic oncologic imaging with PET/CT.

  2014cites this paper
• BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management

  2014cites this paper
• Quantitative Analysis of &ggr;-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers

  2014cites this paper
• Chapitre 6 – Syndromes de prédisposition héréditaire aux cancers pelviens : le rôle du gynécologue

  2013cites this paper
• UTILIZATION OF OVARIAN CANCER SCREENING, RISK- REDUCING SALPINGO-OOPHORECTOMY, AND POST-RRSO HEALTH PRACTICES IN FEMALE BRCA1/BRCA2 MUTATION CARRIERS

  2013cites this paper
• Genetic predisposition syndromes and their management.

  2013cites this paper
• Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran.

  2013cites this paper
• Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

  2013cites this paper
• Genital malignant tumors and precancerous conditions in female carriers of constitutional BRCA 1 gene mutations undergoing prophylactic adnexectomy

  2013cites this paper
• Risk-Reducing Salpingectomy as Preventative Strategy for Pelvic Serous Cancer

  2013cites this paper
• The role of surgeons in cancer management

  2012cites this paper
• Effectiveness of Risk-Reducing Salpingo-Oophorectomy in Preventing Ovarian Cancer in a High-Risk French Canadian Population

  2012cites this paper
• Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

  2012cites this paper
• Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

  2012cites this paper
• Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients

  2012cites this paper
• An unusual BRCA mutation distribution in a high risk cancer genetics clinic

  2012cites this paper
• Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy

  2012cites this paper
• Genetic considerations for a woman's annual gynaecological examination.

  2012cites this paper
• BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families

  2012cites this paper
• Hereditary gynecologic cancers: risk assessment, counseling, testing and management.

  2012cites this paper
• Nowotwory złośliwe i stany przedrakowe narządu płciowego stwierdzane u pacjentek nosicielek mutacji konstytucyjnych genu BRCA1 poddanych operacjom profilaktycznym usunięcia przydatków

  2012cites this paper
• Genetic Counseling and Genetic Testing in the Preoperative Evaluation of Breast Cancer Patients

  2012cites this paper
• Facteurs génétiques à prendre en considération dans le cadre de l’examen gynécologique annuel

  2012cites this paper
• Tumores primitivos de la trompa de Falopio

  2012cites this paper
• Tumeurs primitives de la trompe de Fallope

  2012cites this paper
• BRCA Carriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations

  2012cites this paper
• Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers

  2011cites this paper
• Pathology of hereditary breast cancer

  2011cites this paper
• Outcome of risk‐reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status

  2011cites this paper
• Assessing Ovarian Cancer Risk When Considering Elective Oophorectomy at the Time of Hysterectomy

  2011cites this paper
• Chapitre 4 – Cancers du sein familiaux

  2011cites this paper
• Pathology of hereditary breast cancer

  2011cites this paper
• The Impact of Prophylactic Salpingo-oophorectomy on Health in Women who carry a BRCA1 or BRCA2 Mutation

  2011influential citation
• Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.

  2011cites this paper
• Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

  2011cites this paper
• Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies

  2011cites this paper
• Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer.

  2011cites this paper
• Diagnostik und Therapie maligner Ovarialtumoren

  2011cites this paper
• Risk-Reducing Salpingo-Oophorectomy (RRSO) in BRCA Mutation Carriers: Experience With a Consecutive Series of 111 Patients Using a Standardized Surgical-Pathological Protocol

  2011cites this paper
• Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

  2011cites this paper
• Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.

  2011cites this paper
• Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer.

  2011cites this paper
• [Hereditary gynecologic cancer: the pathologist's point of view].

  2010cites this paper
• Breast Cancer: Risk Assessment and Prevention

  2010cites this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cites this paper
• Les cancers hrditaires de la sphre gyncologique vus par le pathologiste

  2010cites this paper
• Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

  2010cites this paper
• Best Practice & Research Clinical Obstetrics and Gynaecology

  2010cites this paper
• Epidemiology and prognosis of ovarian metastases in colorectal cancer

  2010cites this paper
• Orthotopic and heterotopic ovarian tissue transplantation.

  2010cites this paper